Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11603374B2 · kind B2 · utility
0Cited by
85References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 18, 2019 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | Nov 10, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.